Show simple item record

Article

dc.creatorBernabeu Wittel, Máximoes
dc.date.accessioned2019-09-06T17:16:19Z
dc.date.available2019-09-06T17:16:19Z
dc.date.issued2019-04-18
dc.identifier.citationBernabeu Wittel, M. (2019). Impact of Sarcopenia and Frailty in a Multicenter Cohort of Polypathological Patients. Journal of Clinical Medicine, 8 (4), 1-13.
dc.identifier.issn2077-0383es
dc.identifier.urihttps://hdl.handle.net/11441/89046
dc.description.abstractThe prevalence, relationships and outcomes of sarcopenia and frailty in polypathological patients remain unknown. We performed a multicenter prospective observational study in six hospitals in order to assess prevalence, clinical features, outcome and associated risk factors of sarcopenia and frailty in a hospital-based population of polypathological patients. The cohort was recruited by performing prevalence surveys every 14 days during the inclusion period (March 2012–June 2016). Sarcopenia was assessed by means of EWGSOP criteria and frailty by means of Fried’s criteria. Skeletal muscle mass was measured by tetrapolar bioimpedanciometry. All patients were followed for 12 months. Factors associated with sarcopenia, frailty and mortality were analyzed by multivariate logistic regression, and Kaplan–Meier curves. A total of 444 patients (77.3 ± 8.4 years, 55% males) were included. Sarcopenia was present in 97 patients (21.8%), this being moderate in 54 (12.2%), and severe in 43 (9.6%); frailty was present in 278 patients (62.6%), and 140 (31.6%) were pre-frail; combined sarcopenia and frailty were present in the same patient in 80 (18%) patients. Factors independently associated to the presence of both, sarcopenia and frailty were female gender, older age, different chronic conditions, poor functional status, low body mass index, asthenia and depressive disorders, and low leucocytes and lymphocytes count. Mortality in the 12-months follow-up period was 40%. Patients with sarcopenia, frailty or both survived significantly less than those without these conditions. Sarcopenia and frailty are frequent and interrelated conditions in polypathological patients, shadowing their survival. Their early recognition and management could improve health-related outcomes in this population.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofJournal of Clinical Medicine, 8 (4), 1-13.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectpolypathological patientses
dc.subjectmultimorbidityes
dc.subjectsarcopeniaes
dc.subjectfrailtyes
dc.titleImpact of Sarcopenia and Frailty in a Multicenter Cohort of Polypathological Patientses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.identifier.doi10.3390/jcm8040535es
idus.format.extent13es
dc.journaltitleJournal of Clinical Medicinees
dc.publication.volumen8es
dc.publication.issue4es
dc.publication.initialPage1es
dc.publication.endPage13es

FilesSizeFormatViewDescription
Impact of Sarcopenia.pdf944.8KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional